Literature DB >> 24778273

CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful.

Hye-Jung Kim1, Harvey Cantor.   

Abstract

Research over the past decade has revealed the increasingly complex biologic features of the CD4(+) T-cell lineage. This T-cell subset, which was originally defined on the basis of helper activity in antibody responses, expresses receptors that recognize peptides that have been processed and presented by specialized antigen-presenting cells. At the core of the adaptive immune response, CD4 T cells display a large degree of plasticity and the ability to differentiate into multiple sublineages in response to developmental and environmental cues. These differentiated sublineages can orchestrate a broad range of effector activities during the initiation, expansion, and memory phase of an immune response. The contribution of CD4 cells to host defense against pathogenic invasion and regulation of autoimmunity is now well established. Emerging evidence suggests that CD4 cells also actively participate in shaping antitumor immunity. Here, we outline the biologic properties of CD4 T-cell subsets with an emphasis on their contribution to the antitumor response. ©2014 AACR.

Entities:  

Mesh:

Year:  2014        PMID: 24778273     DOI: 10.1158/2326-6066.CIR-13-0216

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  133 in total

Review 1.  New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.

Authors:  Thomas M Schmitt; Ingunn M Stromnes; Aude G Chapuis; Philip D Greenberg
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 12.531

2.  Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.

Authors:  Kristian Taipale; Ilkka Liikanen; Juuso Juhila; Riku Turkki; Siri Tähtinen; Matti Kankainen; Lotta Vassilev; Ari Ristimäki; Anniina Koski; Anna Kanerva; Iulia Diaconu; Vincenzo Cerullo; Markus Vähä-Koskela; Minna Oksanen; Nina Linder; Timo Joensuu; Johan Lundin; Akseli Hemminki
Journal:  Mol Ther       Date:  2015-08-27       Impact factor: 11.454

3.  CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity.

Authors:  Austin P Huffman; Jeffrey H Lin; Samuel I Kim; Katelyn T Byrne; Robert H Vonderheide
Journal:  JCI Insight       Date:  2020-05-21

4.  A novel dendritic cell-based direct ex vivo assay for detection and enumeration of circulating antigen-specific human T cells.

Authors:  Roberto Carrio; Ge Zhang; Donald R Drake; Brian C Schanen
Journal:  Cytotechnology       Date:  2018-05-07       Impact factor: 2.058

Review 5.  αβ TCR-mediated recognition: relevance to tumor-antigen discovery and cancer immunotherapy.

Authors:  Ellis L Reinherz
Journal:  Cancer Immunol Res       Date:  2015-04       Impact factor: 11.151

Review 6.  Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Authors:  Margaret L Axelrod; Rebecca S Cook; Douglas B Johnson; Justin M Balko
Journal:  Clin Cancer Res       Date:  2018-11-21       Impact factor: 12.531

7.  Human CD4(+) T cells spontaneously detect somatic mutations in cancer cells.

Authors:  Willem W Overwijk
Journal:  Nat Med       Date:  2015-01       Impact factor: 53.440

8.  Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8+ T Cell-Effector Responses.

Authors:  Michael E Birnbaum; Stephanie K Dougan; Eleanor Clancy-Thompson; Christine A Devlin; Paul M Tyler; Mariah M Servos; Lestat R Ali; Katherine S Ventre; M Aladdin Bhuiyan; Patrick T Bruck
Journal:  Cancer Immunol Res       Date:  2018-10-23       Impact factor: 11.151

9.  Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Authors:  Caroline Laheurte; Jeanne Galaine; Laurent Beziaud; Magalie Dosset; Jerome Kerzerho; Claire Jacquemard; Béatrice Gaugler; Christophe Ferrand; Anne Dormoy; François Aubin; Pascale Jacoulet; Virginie Westeel; Christophe Borg; Eric Tartour; Yann Godet; Bernard Maillère; Olivier Adotévi
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

10.  Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity.

Authors:  R Dixon Dorand; Joseph Nthale; Jay T Myers; Deborah S Barkauskas; Stefanie Avril; Steven M Chirieleison; Tej K Pareek; Derek W Abbott; Duncan S Stearns; John J Letterio; Alex Y Huang; Agne Petrosiute
Journal:  Science       Date:  2016-07-21       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.